Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia

Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial

(2015) Waleed Ghanima et al.   LANCET

Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration

(2014) J. B. Bussel et al.   HAEMATOLOGICA

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

(2013) S. Gudbrandsdottir et al.   BLOOD

Next-generation-sequencing-spectratyping reveals public T-cell receptor repertoires in pediatric very severe aplastic anemia and identifies a   chain CDR3 sequence associated with hepatitis-induced pathogenesis

(2013) P. F. I. Krell et al.   HAEMATOLOGICA

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

(2012) C. Muller et al.   BLOOD

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

(2012) V. L. Patel et al.   BLOOD

Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response

(2012) U. Jager et al.   HAEMATOLOGICA

B Cell Activating Factor Gene Polymorphisms in Patients With Risk of Idiopathic Thrombocytopenic Purpura

(2011) Samah M. Abdel-Hamid et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register

(2011) M. M. SOLIMAN et al.   JOURNAL OF RHEUMATOLOGY

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

(2010) F. Zaja et al.   BLOOD

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Idiopathic thrombocytopenic purpura in elderly patients: A study of 47 cases from a single reference center

(2008) Samira Daou et al.   European Journal of Internal Medicine